Transport mechanisms governing serotonin clearance in vivo revealed by high-speed chronoamperometry

J Neurosci Methods. 2005 Apr 15;143(1):49-62. doi: 10.1016/j.jneumeth.2004.09.011.

Abstract

High-speed chronoamperometry was used to determine the kinetics of clearance of exogenously applied serotonin (5-HT) in the dorsal raphe nucleus (DRN), dentate gyrus, CA3 region of the hippocampus or corpus callosum of anesthetized rats. Maximal velocity (Vmax) for 5-HT clearance was greatest in the DRN > dentate gyrus > CA3 > corpus callosum. Apparent affinity (K(T)) of the serotonin transporter (5-HTT) was similar in DRN and CA3 but greater in dentate gyrus and corpus callosum. A 90% loss of norepinephrine transporters (NET) produced by 6-hydroxydopamine pretreatment, resulted in a two-fold reduction in Vmax and a 30% decrease in K(T) in the dentate gyrus, but no change in kinetic parameters in the CA3 region. Pretreatment with 5,7-dihydroxytryptamine that resulted in a 90% reduction in 5-HTT density, modestly reduced Vmax in dentate gyrus but not in CA3. The same treatment had no effect on K(T) in the dentate gyrus but increased K(T) two-fold in the CA3. Neurotoxin treatments had no effect on 5-HT clearance in the corpus callosum. In hippocampal regions of intact rats, local application of the selective serotonin reuptake inhibitor, fluvoxamine, inhibited 5-HT clearance most robustly when the extracellular concentration of 5-HT was less than the K(T) value. By contrast, the NET antagonist, desipramine, significantly inhibited 5-HT clearance when extracellular concentrations of 5-HT were greater than the K(T) value. These data indicate that hippocampal uptake of 5-HT may be mediated by two processes, one with high affinity but low capacity (i.e. the 5-HTT) and the other with low affinity but a high capacity (i.e. the NET). These data show for the first time in the whole animal that 5-HT clearance in brain is regionally distinct with regard to rate and affinity.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 5,7-Dihydroxytryptamine / pharmacology
  • Adrenergic Agents / pharmacology
  • Adrenergic Uptake Inhibitors / pharmacology
  • Animals
  • Binding Sites / drug effects
  • Binding Sites / physiology
  • Biological Transport / physiology
  • Brain / metabolism*
  • Brain Chemistry / physiology*
  • Corpus Callosum / drug effects
  • Corpus Callosum / metabolism
  • Down-Regulation / drug effects
  • Down-Regulation / physiology
  • Electrochemistry
  • Hippocampus / drug effects
  • Hippocampus / metabolism
  • Kinetics
  • Male
  • Membrane Glycoproteins / metabolism*
  • Membrane Transport Proteins / metabolism*
  • Metabolic Clearance Rate / physiology
  • Nerve Tissue Proteins / metabolism*
  • Neurochemistry / methods*
  • Norepinephrine Plasma Membrane Transport Proteins
  • Oxidopamine / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Selective Serotonin Reuptake Inhibitors / pharmacology
  • Serotonin / metabolism
  • Serotonin / pharmacokinetics*
  • Serotonin Agents / pharmacology
  • Serotonin Plasma Membrane Transport Proteins
  • Symporters / antagonists & inhibitors
  • Symporters / metabolism
  • Time Factors

Substances

  • Adrenergic Agents
  • Adrenergic Uptake Inhibitors
  • Membrane Glycoproteins
  • Membrane Transport Proteins
  • Nerve Tissue Proteins
  • Norepinephrine Plasma Membrane Transport Proteins
  • Serotonin Agents
  • Serotonin Plasma Membrane Transport Proteins
  • Serotonin Uptake Inhibitors
  • Slc6a2 protein, rat
  • Slc6a4 protein, rat
  • Symporters
  • 5,7-Dihydroxytryptamine
  • Serotonin
  • Oxidopamine